why choose us

First received: March 27, 2023

Clinical Trial: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Study Status: Completed

Recruit Status: RECRUITING

Condition: Type 2 Diabetes

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Brief Summary: The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.The study will last approximately 2 years may include up to 27 visits.

Read more